SG10201805934RA - Antibodies directed against interleukin-33 (il-33) - Google Patents

Antibodies directed against interleukin-33 (il-33)

Info

Publication number
SG10201805934RA
SG10201805934RA SG10201805934RA SG10201805934RA SG10201805934RA SG 10201805934R A SG10201805934R A SG 10201805934RA SG 10201805934R A SG10201805934R A SG 10201805934RA SG 10201805934R A SG10201805934R A SG 10201805934RA SG 10201805934R A SG10201805934R A SG 10201805934RA
Authority
SG
Singapore
Prior art keywords
chain polypeptide
directed against
antibodies directed
against interleukin
interleukin
Prior art date
Application number
SG10201805934RA
Other languages
English (en)
Inventor
Robert A Horlick
David J King
Andrew John Mcknight
Original Assignee
Anaptysbio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anaptysbio Inc filed Critical Anaptysbio Inc
Publication of SG10201805934RA publication Critical patent/SG10201805934RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG10201805934RA 2014-01-10 2015-01-09 Antibodies directed against interleukin-33 (il-33) SG10201805934RA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461925946P 2014-01-10 2014-01-10

Publications (1)

Publication Number Publication Date
SG10201805934RA true SG10201805934RA (en) 2018-08-30

Family

ID=53524474

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201605580RA SG11201605580RA (en) 2014-01-10 2015-01-09 Antibodies directed against interleukin-33 (il-33)
SG10201805934RA SG10201805934RA (en) 2014-01-10 2015-01-09 Antibodies directed against interleukin-33 (il-33)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201605580RA SG11201605580RA (en) 2014-01-10 2015-01-09 Antibodies directed against interleukin-33 (il-33)

Country Status (14)

Country Link
US (4) US10059764B2 (fr)
EP (1) EP3092253B1 (fr)
JP (2) JP2017503506A (fr)
KR (1) KR102446386B1 (fr)
CN (1) CN106103480B (fr)
AU (1) AU2015204674B2 (fr)
BR (1) BR112016016020B1 (fr)
CA (1) CA2936366A1 (fr)
ES (1) ES2866935T3 (fr)
MX (2) MX2016009047A (fr)
NZ (1) NZ722445A (fr)
RU (2) RU2693084C2 (fr)
SG (2) SG11201605580RA (fr)
WO (1) WO2015106080A2 (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008012991A (es) 2006-04-07 2008-10-17 Procter & Gamble Anticuerpos que ligan proteina tirosina fosfatasa humana beta (hptpbeta) y los usos de estos.
CN104039351A (zh) 2011-10-13 2014-09-10 阿尔皮奥治疗学股份有限公司 用于治疗血管渗漏综合征和癌症的方法
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
AU2014240101B2 (en) 2013-03-15 2018-05-17 Regeneron Pharmaceuticals, Inc. IL-33 antagonists and uses thereof
WO2015099175A1 (fr) 2013-12-26 2015-07-02 田辺三菱製薬株式会社 Anticorps monoclonal neutralisant humain anti-il-33
BR112016016020B1 (pt) 2014-01-10 2024-02-27 Anaptysbio, Inc Agente de ligação (il-33) de interleucina-33, célula procariótica isolada, composição e uso do referido agente
EP3218515B1 (fr) 2014-11-10 2023-04-26 F. Hoffmann-La Roche AG Méthodes thérapeutiques et diagnostiques pour les troubles à médiation par l'il-33
EA201791029A1 (ru) 2014-11-10 2017-12-29 Дженентек, Инк. Антитела против интерлейкина-33 и их применение
BR112018014247A2 (pt) * 2016-01-14 2018-12-18 Anaptysbio Inc inibição de reação alérgica usando um inibidor il-33
MX2018013038A (es) * 2016-04-27 2019-03-28 Pfizer Anticuerpos anti-il-33, composiciones, metodos y usos de los mismos.
CA3030298A1 (fr) 2016-07-20 2018-01-25 Aerpio Therapeutics, Inc. Anticorps monoclonaux humanises ciblant ve-ptp (hptp-ss)
JOP20190093A1 (ar) * 2016-10-28 2019-04-25 Lilly Co Eli أجسام مضادة لـ il-33 واستخداماتها
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
ES2971126T3 (es) 2016-12-19 2024-06-03 Medimmune Ltd Anticuerpos contra LIF y usos de los mismos
WO2018115960A1 (fr) 2016-12-19 2018-06-28 Mosaic Biomedicals, S.L. Anticorps anti-lif et leurs utilisations
RU2771485C2 (ru) 2017-02-10 2022-05-04 Дженентек, Инк. Антитела против триптазы, их композиции и применения
EP3610041A1 (fr) 2017-04-13 2020-02-19 Regeneron Pharmaceuticals, Inc. Traitement et inhibition des maladies pulmonaires inflammatoires chez des patients possédant des allèles de risque dans les gènes codant pour l'il33 et il1rl1
WO2019045075A1 (fr) 2017-08-31 2019-03-07 田辺三菱製薬株式会社 Agent thérapeutique contenant un antagoniste de l'il-33 pour traiter l'endométriose
WO2019074912A1 (fr) 2017-10-09 2019-04-18 Anaptysbio, Inc. Therapie anti-il-33 pour la dermatite atopique
AU2019218128A1 (en) 2018-02-09 2020-09-17 Genentech, Inc. Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
WO2019183639A1 (fr) * 2018-03-23 2019-09-26 Anaptysbio, Inc. Inhibition de la réaction allergique à un allergène arachide à l'aide d'un inhibiteur de l'il-33
IL277890B2 (en) 2018-04-11 2024-03-01 Regeneron Pharma Methods for quantification of IL-33
TW202021983A (zh) 2018-09-21 2020-06-16 美商安納普提斯生物公司 用於嗜伊紅性氣喘之抗il-33療法
CN113164597A (zh) 2018-09-24 2021-07-23 爱尔皮奥制药公司 靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体
JP2023500492A (ja) 2019-11-04 2023-01-06 メドイミューン・リミテッド Ｉｌ－３３アンタゴニストの使用方法
CA3158366A1 (fr) 2019-11-04 2021-05-14 Medimmune Limited Agent therapeutique anti-il-33 pour le traitement de troubles renaux
US20230338387A1 (en) 2020-02-05 2023-10-26 Nof Corporation Agent For Treating Or Preventing Pancreatic Fistula
PE20230252A1 (es) 2020-03-13 2023-02-07 Genentech Inc Anticuerpos anti-interleucina-33 y sus usos de estos
WO2021180858A1 (fr) 2020-03-13 2021-09-16 Medimmune Limited Méthodes thérapeutiques pour le traitement de sujets présentant des allèles à risque dans l'il33
CN115867575A (zh) 2020-04-06 2023-03-28 免疫医疗有限公司 用il-33轴结合拮抗剂治疗急性呼吸窘迫综合征
BR112022022620A2 (pt) 2020-05-11 2022-12-20 Medimmune Ltd Formulações de anticorpos anti-il-33
US12065507B2 (en) * 2020-06-01 2024-08-20 University Of Kentucky Research Foundation Compounds and methods for use in connection with opioid use disorders
WO2022011037A2 (fr) * 2020-07-07 2022-01-13 The General Hospital Corporation Inhibition de l'interleukine 33 (il-33) pour le traitement du cancer, de la fibrose et de l'inflammation
KR20220022226A (ko) * 2020-08-18 2022-02-25 성균관대학교산학협력단 Il-33 항체 또는 이의 항원 결합 단편
CN114249825A (zh) 2020-09-25 2022-03-29 三生国健药业（上海）股份有限公司 结合人il-33的抗体、其制备方法和用途
CN113603775B (zh) 2021-09-03 2022-05-20 江苏荃信生物医药股份有限公司 抗人白介素-33单克隆抗体及其应用
EP4430072A1 (fr) 2021-11-10 2024-09-18 Genentech, Inc. Anticorps anti-interleukine-33 et leurs utilisations
TW202402790A (zh) 2022-03-25 2024-01-16 英商梅迪繆思有限公司 減少呼吸系統感染之方法
WO2024038185A1 (fr) 2022-08-19 2024-02-22 Medimmune Limited Procédé de sélection de patients pour le traitement avec un antagoniste de l'axe d'il-33

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4828981A (en) 1983-08-24 1989-05-09 Synbiotics Corporation Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
JP3150340B2 (ja) 1990-11-13 2001-03-26 イムネクス コーポレイション 二機能選択可能融合遺伝子
JPH09500783A (ja) 1993-05-21 1997-01-28 ターゲッティッド ジェネティクス コーポレイション シトシンデアミナーゼ（ｃｄ）遺伝子に基づく二機能性選択融合遺伝子
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
FR2814642B1 (fr) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
DE60226641D1 (de) 2001-12-03 2008-06-26 Amgen Fremont Inc Antikörperkategorisierung auf der grundlage von bindungseigenschaften
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
US20070048785A1 (en) 2004-06-09 2007-03-01 Lin Laura L Anti-IL-13 antibodies and complexes
EA021669B1 (ru) 2005-07-18 2015-08-31 Амджен Инк. Нейтрализующие антитела человека против b7rp1
US8147817B2 (en) 2006-05-04 2012-04-03 The Brigham And Women's Hospital, Inc. IL-33 in the treatment and diagnosis of diseases and disorders
US7560530B1 (en) 2006-07-20 2009-07-14 Schering Corporation IL-33 receptor
MX2009002554A (es) 2006-09-08 2009-03-20 Abbott Lab Proteinas de enlace de interleucina-13.
WO2008103474A1 (fr) 2007-02-20 2008-08-28 Anaptysbio, Inc. Procédés de production de pharmacothèques, et leurs utilisations
IE20080331A1 (en) 2007-04-26 2009-07-08 Trinity College Dublin Products for altering cytokine activity and methods therefor
US20100260770A1 (en) * 2007-05-18 2010-10-14 Medimmune, Llc Il-33 in inflammatory disease
CA2729499A1 (fr) 2008-06-30 2010-01-07 Morphotek, Inc. Anticorps anti-gd2 et procedes et utilisations associes a ceux-ci
UA102722C2 (en) 2009-01-29 2013-08-12 Эббви Инк. Il-1 binding proteins
WO2011031600A1 (fr) * 2009-09-10 2011-03-17 Schering Corporation Utilisation d'antagonistes de l'il-33 à des fins de traitement des maladies fibrotiques
ES2547872T3 (es) 2009-10-15 2015-10-09 Avaxia Biologics, Inc. Agentes terapéuticos de anticuerpos con actividad local en el tracto digestivo
BR112012031071B1 (pt) 2010-05-14 2021-08-10 Abbvie Inc Proteínas de ligação à il-1 e composição farmacêutica compreendendo as referidas proteínas de ligação
CN105440134A (zh) * 2010-08-16 2016-03-30 安姆根公司 结合肌肉生长抑制素的抗体、组合物和方法
EA028054B1 (ru) 2010-11-01 2017-10-31 Мелинта Терапьютикс, Инк. Фармацевтические композиции
AR084342A1 (es) 2010-12-16 2013-05-08 Genentech Inc Diagnostico y tratamientos relacionados con la inhibicion de th2
WO2012103240A2 (fr) 2011-01-25 2012-08-02 Eleven Biotherapeutics, Inc. Agents de liaison à un récepteur
FR2972006B1 (fr) 2011-02-24 2016-03-25 Centre Nat Rech Scient Nouveaux fragments d'il-33 superactifs et leurs utilisations
SG11201401791WA (en) 2011-10-24 2014-08-28 Abbvie Inc Immunobinders directed against sclerostin
JP2015502340A (ja) 2011-10-27 2015-01-22 エヌケーティー セラピューティクス インコーポレーテッドＮｋｔ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． ｉＮＫＴに対するヒト化抗体
EP2817417B1 (fr) 2012-02-24 2017-10-25 Children's Hospital Medical Center Profils d'expression de micro-arn sophagiens dans sophagite éosinophile
US9212227B2 (en) 2012-04-30 2015-12-15 Janssen Biotech, Inc. ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
UY34813A (es) 2012-05-18 2013-11-29 Amgen Inc Proteínas de unión a antígeno dirigidas contra el receptor st2
BR112015001859A2 (pt) 2012-07-31 2017-07-04 Novartis Ag tratamento de inflamação utilizando serelaxina
WO2014062621A1 (fr) 2012-10-15 2014-04-24 Stc.Unm Traitement de troubles basés sur l'autophagie et compositions pharmaceutiques, tests et kits de diagnostic et de dépistage associés
CA2894219C (fr) 2012-12-10 2020-08-11 Vib Vzw Nouveaux inhibiteurs de l'interleukine-33
WO2014126277A1 (fr) 2013-02-14 2014-08-21 건국대학교 산학협력단 Composition d'un nouveau récepteur de l'interleukine-33 et d'une protéine de liaison et son utilisation
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
AU2014240101B2 (en) 2013-03-15 2018-05-17 Regeneron Pharmaceuticals, Inc. IL-33 antagonists and uses thereof
CA2918105C (fr) 2013-08-12 2023-02-28 Medimmune, Llc Procedes pour reduire des taux d'exacerbation d'asthme a l'aide de benralizumab
KR101567758B1 (ko) 2013-10-17 2015-11-11 인하대학교 산학협력단 항-Siglec-8 항체 또는 항-Siglec-F 항체, 및 항-IL-33 항체를 포함하는 알러지 질환의 예방 또는 치료용 조성물
AR098155A1 (es) 2013-10-23 2016-05-04 Genentech Inc Métodos para diagnosticar y tratar trastornos eosinofílicos
WO2015099175A1 (fr) 2013-12-26 2015-07-02 田辺三菱製薬株式会社 Anticorps monoclonal neutralisant humain anti-il-33
BR112016016020B1 (pt) 2014-01-10 2024-02-27 Anaptysbio, Inc Agente de ligação (il-33) de interleucina-33, célula procariótica isolada, composição e uso do referido agente
WO2015143343A2 (fr) 2014-03-21 2015-09-24 The Brigham And Women's Hospital, Inc. Procédés et compositions pour le traitement de maladies immunitaires ou de troubles et/ou la surveillance thérapeutique
GB201406608D0 (en) 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
EP3134120B1 (fr) 2014-04-21 2024-01-24 The Children's Hospital of Philadelphia Compositions et méthodes pour le traitement de troubles liés aux cytokines
EA201791029A1 (ru) 2014-11-10 2017-12-29 Дженентек, Инк. Антитела против интерлейкина-33 и их применение
EP3218515B1 (fr) 2014-11-10 2023-04-26 F. Hoffmann-La Roche AG Méthodes thérapeutiques et diagnostiques pour les troubles à médiation par l'il-33
CA2978449A1 (fr) 2015-03-02 2016-09-09 180 Therapeutics Lp Methode de traitement d'un trouble fibrotique localise a l'aide d'un antagoniste de l'il-33
EP3095440B1 (fr) 2015-05-19 2020-01-15 PLS-Design GmbH Immunothérapie spécifique d'un antigène à l'aide de liposomes de tolérance
MA50638A (fr) 2015-10-06 2020-08-05 Regeneron Pharma Biomarqueurs associés aux maladies médiées par l'interleukine-33 (il-33) et leurs utilisations
BR112018014247A2 (pt) 2016-01-14 2018-12-18 Anaptysbio Inc inibição de reação alérgica usando um inibidor il-33

Also Published As

Publication number Publication date
US20160333090A1 (en) 2016-11-17
EP3092253B1 (fr) 2021-03-17
JP6882702B2 (ja) 2021-06-02
RU2693084C2 (ru) 2019-07-01
ES2866935T3 (es) 2021-10-20
US10836820B2 (en) 2020-11-17
KR102446386B1 (ko) 2022-09-22
JP2020018309A (ja) 2020-02-06
RU2016132757A (ru) 2018-02-16
WO2015106080A3 (fr) 2015-09-11
US10059764B2 (en) 2018-08-28
SG11201605580RA (en) 2016-10-28
CA2936366A1 (fr) 2015-07-16
JP2017503506A (ja) 2017-02-02
RU2019118984A (ru) 2019-08-06
KR20160132006A (ko) 2016-11-16
BR112016016020A2 (pt) 2018-05-22
MX2016009047A (es) 2017-04-13
AU2015204674A1 (en) 2016-08-25
AU2015204674B2 (en) 2020-09-03
MX2020001272A (es) 2020-07-20
CN106103480A (zh) 2016-11-09
US20180346562A1 (en) 2018-12-06
WO2015106080A2 (fr) 2015-07-16
BR112016016020B1 (pt) 2024-02-27
US11999783B2 (en) 2024-06-04
US20240294631A1 (en) 2024-09-05
NZ722445A (en) 2022-07-01
US20210040198A1 (en) 2021-02-11
CN106103480B (zh) 2021-10-22
EP3092253A4 (fr) 2017-11-29
RU2016132757A3 (fr) 2018-07-16
EP3092253A2 (fr) 2016-11-16

Similar Documents

Publication Publication Date Title
MX2020001272A (es) Anticuerpos dirigidos contra interleucina-33 (il-33).
ZA201706740B (en) Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
MX2022002364A (es) Anticuerpos anti-pd-l1.
MX2023001791A (es) Anticuerpos dirigidos contra receptor de interleucina 36 (il-36r).
MX2018015592A (es) Anticuerpos inhibidores de puntos de control biespecificos.
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
MX2022005177A (es) Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos.
PH12017502019A1 (en) Heterodimeric antibodies that bind cd3 and tumor antigens
MX2021003704A (es) Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales.
MX2024006565A (es) Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos.
NZ738008A (en) Tigit-binding agents and uses thereof
MX2015015037A (es) Anticuerpos dirigidos contra la proteina muerte programada-1 (pd-1).
SG10201900571YA (en) Anti-pd-1 antibodies
NZ724815A (en) Humanized antibodies that bind lgr5
ZA201800804B (en) Novel anti-human gpvi antibodies and uses thereof
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
MX2023006786A (es) Anticuerpos inmunomoduladores biespecificos que se fijan a receptores coestimuladores y de puntos de control.
EA201891528A1 (ru) Композиции и способы обнаружения и лечения рака желудка
MX2018009218A (es) Anticuerpos de cgrp y sus usos.
WO2015116569A3 (fr) Anticorps dirigés contre la famille des récepteurs à domaine discoïdine, élément 1 (ddr1)
NZ733664A (en) Antibodies that bind human c6 and uses thereof
MX2019002349A (es) Anticuerpos inmunomoduladores biespecíficos que se fijan a receptores coestimuladores y de puntos de control.
EA202092572A1 (ru) Композиции и способы обнаружения и лечения рака пищевода